<DOC>
	<DOCNO>NCT00742248</DOCNO>
	<brief_summary>The purpose study demonstrate equivalent efficacy two different formulation formoterol ( pMDI use HFA-134 propellant dry powder ) lung function adult patient partially reversible COPD .</brief_summary>
	<brief_title>Formoterol Via pMDI HFA-134a Propellant DPI Partially Reversible Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>The present study aim investigate effect single 12 µg dose short 7-day course formoterol HFA-134a , compare formoterol DPI formulation , specific parameter appropriate assessment single-dose short-term effect COPD . This study design assess efficacy traditional use FEV1 . Furthermore , use efficacy parameter change exertion tolerance dyspnoea , dynamic static volume measure use whole body plethysmograph , TLC , RV , IC airways conductance sGAW include . This double blind , double dummy , multicentre , randomise , placebo-controlled , cross-over study least 36 adult patient partially reversible COPD . The two test treatment placebo administer single repeat ( twice daily 7 day ) dose cycle ( minimum 2 day maximum 7 day wash-out cycle ) . Seven clinic visit total take place start end run-in period , first last dose treatment cycle ( placebo two active treatment test ) , acceptable variation maximum ± 1 day respect schedule day end treatment cycle ( i.e . treatment placebo active drug may range 6 8 day ) .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Patients either sex age &gt; 40 year . Clinical diagnosis partially reversible COPD , without chronic symptom , line follow recommendation National Heart Lung Blood Institute/World Health Organisation ( NHLBI/WHO ) Global Initiative Chronic Obstructive Lung Disease ( GOLD ) ( 22 ) : Postbronchodilator FEV1 ≥ 30 % &lt; 80 % predict normal value , least 0.7 L ( less 0.7 L , FEV1 must ≥ 40 % predict normal value ) FEV1/FVC ratio &lt; 70 % . Positive partial response reversibility test screen visit , define increase baseline value least 5 % percentage predict normal value ( postdosing minus predosing/predosing x 100 ) FEV1 measurement 30 minute follow 4 puff ( 4 x 100 µg ) inhale salbutamol pMDI . Current past tobacco heavy smoking habit ( define smoking &gt; 20 pack year , 1 pack year = 20 cigarettes/day 1 year equivalent ) . A cooperative attitude ability train use correctly pMDI AerolizerTM inhaler . Written inform consent obtain . Evidence COPD exacerbation and/or symptomatic infection airways previous 4 week require antibiotic therapy . History clinically significant disease whose sequelae and/or treatment interfere result present study . Presence asthma . Evidence bronchiectases . History inadequate cardiac , hepatic and/or renal function . History coronary artery disease , myocardial infarction , cerebrovascular disease , cardiac arrhythmia , severe hypertension diabetes mellitus . Other haemodynamic relevant rhythm disturbance ( include atrial flutter atrial fibrillation ventricular response , bradycardia ( ≤ 55 bpm ) , evidence atrialventricular ( AV ) block ECG 1st degree . History percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) . Patients serum potassium value ≤ 3.5 mEq/L and/or serum glucose value ≥ 140 mg/dL . Patients abnormal QTc interval value ECG test , define &gt; 450 msec male &gt; 470 msec female . Evidence posture gait disturbance , impairment limb coordination due cause . Patients take oral corticosteroid last month prior study entry . Patients take inhaled longacting β2agonists anticholinergics last 48 hour . Patients already take inhaled corticosteroid ( include nasal ) , sodium cromoglycate nedocromil sodium , leukotriene antagonist , xanthyne derivative , mucolytics , antitussive dose change last month study entry likely change total study period . History hypersensitivity sympathomimetic drug . Patients take βantagonists , tricyclic antidepressant monoamine oxidase inhibitor ( MAOI ) . Pregnant lactating female female risk pregnancy , i.e . demonstrate adequate contraception ( i.e . barrier method , intrauterine device , hormonal treatment sterilization ) . A pregnancy test recommend Patients postbronchodilator FEV1 &lt; 0.7 L predict normal FEV1 &lt; 40 % . Patients require longterm oxygen therapy .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>COPD</keyword>
</DOC>